Haemanthus: A New Venture in Health Optimization

Haemanthus: A New Venture in Health Optimization

Billy Evans, a partner of Theranos founder Elizabeth Holmes, has launched a new startup called Haemanthus. The company’s goal is to deliver human health optimization through blood testing.

Startup Overview

  • Haemanthus has begun pitching its idea to investors.
  • Reports from The New York Times indicate that two investors were shown the startup’s marketing materials.
  • The materials claim that Haemanthus has developed a machine that uses lasers to analyze blood, saliva, and urine samples.

Claims and Verification

  • The machine allegedly can detect cancer and infections in these samples.
  • However, these claims have not been independently verified by outside experts.

Business Strategy

  • Haemanthus plans to start by improving pet health before expanding its services to humans.
  • To achieve this goal, the company is seeking more than $50 million in funding.

Background on Theranos

  • Theranos was founded by Holmes in 2003 with the aim of developing portable devices for testing diseases using just a few drops of blood from fingers rather than vials drawn from veins at hospitals or clinics.
  • However, Theranos’ technology was later found not to work as promised.
  • Holmes was convicted on four counts of fraud related to her role at Theranos after being charged with multiple counts, including conspiracy and wire fraud.

Legal Issues

  • The company collapsed after it emerged that many tests were conducted on traditional machines rather than on its own proprietary technology as claimed.
  • Holmes’ conviction followed her acquittal on four other charges related to conspiracy against an investor who had backed her firm while also lying about his identity as an ex-husband of former U.S. President George W. Bush’s daughter, Barbara Bush.
  • Holmes’ lawyers have stated they will appeal all convictions, though no timeline has been provided.

Current Challenges for Evans

  • Billy Evans faces civil lawsuits filed by former employees who claim he knew about problems with Theranos’ technology but failed to report them or take action.
  • Evans declined to comment when asked if he knew anything about any issues with Haemanthus’s technology.

Company Statement

A spokesperson for Haemanthus stated:

“We are excited about our mission and we believe our products will make a real difference in people’s lives.”

FacebooktwitterlinkedinrssyoutubeFacebooktwitterlinkedinrssyoutube
FacebooktwitterredditpinterestlinkedinmailFacebooktwitterredditpinterestlinkedinmail

Leave a Comment

Your email address will not be published. Required fields are marked *